Alpha-interferon in the treatment of idiopathic myelofibrosis

Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia.

Leukemia·2017

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.

Annals of oncology : official journal of the European Society for Medical Oncology·2015

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

Blood cancer journal·2015

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes.

Blood cancer journal·2015

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.

Leukemia·2013

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.

Leukemia·2013

Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial.

British journal of haematology·2026

Carrying a crisis: The risk of a painful sickle cell crisis during pregnancy.

British journal of haematology·2026

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups.

British journal of haematology·2026

Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification-Insights from chromosome count and cytogenetic abnormalities.

British journal of haematology·2026

A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial.

British journal of haematology·2026

Interplay between fibroblast growth factor 9 (FGF9) and CD44 underlies 46,XY disorders of sex development in Kruppel-like factor 1 (KLF-1)-E325K-associated congenital dyserythropoietic anaemia (CDA-IV).

British journal of haematology·2026

Extracellular vesicle-based therapies in IBD: immunomodulation, regeneration, and translation.

Frontiers in immunology·2026

Immune cell-derived exosomes in cancer: double-edged mechanisms of antitumor immunity and tumor progression.

Frontiers in immunology·2026

Review-Nanozyme-Based Immunosensors and Immunoassays: Recent Developments and Future Trends.

Journal of the Electrochemical Society·2026

The transformative potential of lipid nanoparticles tailored for acute myeloid leukemia immunotherapy.

Frontiers in immunology·2026

Adjuvant immune checkpoint inhibitors across solid tumors: a meta-analysis of phase II-III randomized trials.

Frontiers in oncology·2026

Recent Advances in Artificial Intelligence for Endoscopic and Multimodal Assessment of Inflammatory Bowel Disease: A Review.

International journal of general medicine·2026

Related Experiment Videos

Alpha-interferon in the treatment of idiopathic myelofibrosis

Related Concept Videos

Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia.

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes.

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.

Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial.

Carrying a crisis: The risk of a painful sickle cell crisis during pregnancy.

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups.

Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification-Insights from chromosome count and cytogenetic abnormalities.

A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial.

Interplay between fibroblast growth factor 9 (FGF9) and CD44 underlies 46,XY disorders of sex development in Kruppel-like factor 1 (KLF-1)-E325K-associated congenital dyserythropoietic anaemia (CDA-IV).

Extracellular vesicle-based therapies in IBD: immunomodulation, regeneration, and translation.

Immune cell-derived exosomes in cancer: double-edged mechanisms of antitumor immunity and tumor progression.

Review-Nanozyme-Based Immunosensors and Immunoassays: Recent Developments and Future Trends.

The transformative potential of lipid nanoparticles tailored for acute myeloid leukemia immunotherapy.

Adjuvant immune checkpoint inhibitors across solid tumors: a meta-analysis of phase II-III randomized trials.

Recent Advances in Artificial Intelligence for Endoscopic and Multimodal Assessment of Inflammatory Bowel Disease: A Review.

Related Experiment Videos

Alpha-interferon in the treatment of idiopathic myelofibrosis

Related Concept Videos

Related Articles